Double Blind Controlled Trials of Cholecystokinin Octapeptide in Neuroleptic-refractory Schizophrenia

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1987 Jan 1

PMID 2881320

Citations 2

Authors

E Peselow

B Angrist

A Sudilovsky

J Corwin

J Siekierski

F Trent

J Rotrosen

Affiliations

Soon will be listed here.

Abstract

A group of 14 schizophrenics who remained symptomatic after neuroleptic treatment received either 0.02 mcg/kg CCK-8 or saline placebo intravenously. Thereafter, 13 received the alternative infusion as a crossover treatment. A second group of 16 such patients received 0.04 mcg/kg CCK-8 or saline intravenously and, thereafter, 14 of these received the alternative infusion as a crossover treatment. Psychopathology was rated prior to, 2-3 h post, and on days 3, 5 and 7 after each infusion. Ratings consisted of the BPRS, the Abrams and Taylor Scale for Emotional Blunting, the Hamilton Anxiety Scale and a Schneiderian "Positive" symptom scale abstracted from the President State Examination. Parallel groups and cross over design analyses failed to show efficacy for CCK-8.

Citing Articles

Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

De Wied D, Sigling H Neurotox Res. 2003; 4(5-6):453-468.

PMID: 12754159 DOI: 10.1080/10298420290031432.

CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.

Weiss F, Ettenberg A, Koob G Psychopharmacology (Berl). 1989; 99(3):409-15.

PMID: 2574480 DOI: 10.1007/BF00445568.

References

Hokfelt T, Skirboll L, Rehfeld J, Goldstein M, Markey K, DANN O . A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience. 1980; 5(12):2093-124. DOI: 10.1016/0306-4522(80)90127-x. View

Itoh H, Tanoue S, Yagi G, Tateyama M, Kamisada M, Fujii Y . Clinical study on the psychotropic effects of caerulein--an open clinical trial in chronic schizophrenic patients. Keio J Med. 1982; 31(3):71-95. DOI: 10.2302/kjm.31.71. View

Skirboll L, Grace A, Hommer D, Rehfeld J, Goldstein M, Hokfelt T . Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience. 1981; 6(11):2111-24. DOI: 10.1016/0306-4522(81)90002-6. View

Murphy R, Schuster D . Modulation of [3H]-dopamine binding by cholecystokinin octapeptide (CCK-8). Peptides. 1982; 3(3):539-43. DOI: 10.1016/0196-9781(82)90123-1. View

OLSON G, Peterson D . Intermittent chemotherapy for chronic psychiatric inpatients. J Nerv Ment Dis. 1962; 134:145-9. DOI: 10.1097/00005053-196202000-00005. View

Innis R, Synder S . Cholecystokinin receptor binding in brain and pancreas: regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. Eur J Pharmacol. 1980; 65(1):123-4. DOI: 10.1016/0014-2999(80)90221-6. View

WHITTAKER C, HOY R . Withdrawal of perphenazine in chronic schizophrenia. Br J Psychiatry. 1963; 109:422-7. DOI: 10.1192/bjp.109.460.422. View

Itoh S, Katsuura G . Suppressive action of cholecystokinin octapeptide on the behavioral effects of L-DOPA in the rat. Eur J Pharmacol. 1981; 75(4):313-6. DOI: 10.1016/0014-2999(81)90559-8. View

Chase T, Barone P, Bruno G, Cohen S, Juncos J, Knight M . Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric disease. Ann N Y Acad Sci. 1985; 448:553-61. DOI: 10.1111/j.1749-6632.1985.tb29948.x. View

10.

MOROJI T, Watanabe N, Aoki N, Itoh S . Antipsychotic effects of ceruletide (caerulein) on chronic schizophrenia. Arch Gen Psychiatry. 1982; 39(4):485-6. DOI: 10.1001/archpsyc.1982.04290040079011. View

11.

Abrams R, Taylor M . A rating scale for emotional blunting. Am J Psychiatry. 1978; 135(2):226-9. DOI: 10.1176/ajp.135.2.226. View

12.

Lotstra F, Verbanck P, Mendlewicz J, Vanderhaeghen J . No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study. Biol Psychiatry. 1984; 19(6):877-82. View

13.

Albus M, Ackenheil M, Munch U, Naber D . Ceruletide: a new drug for the treatment of schizophrenic patients?. Arch Gen Psychiatry. 1984; 41(5):528. DOI: 10.1001/archpsyc.1984.01790160114018. View

14.

Fuxe K, Agnati L, Benfenati F, Cimmino M, Algeri S, Hokfelt T . Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand. 1981; 113(4):567-9. DOI: 10.1111/j.1748-1716.1981.tb06942.x. View

15.

ZETLER G . Central depressant effects of caerulein and cholecystokinin octapeptide (CCK-8) differ from those of diazepam and haloperidol. Neuropharmacology. 1981; 20(3):277-83. DOI: 10.1016/0028-3908(81)90134-9. View

16.

Fekete M, Kadar T, Penke B, Kovacs K, Telegdy G . Influence of cholecystokinin octapeptide sulfate ester on brain monoamine metabolism in rats. J Neural Transm. 1981; 50(2-4):81-8. DOI: 10.1007/BF01249131. View

17.

Widerlov E, Kalivas P, Lewis M, Prange Jr A, Breese G . Influence of cholecystokinin on central monoaminergic pathways. Regul Pept. 1983; 6(2):99-109. DOI: 10.1016/0167-0115(83)90003-4. View

18.

Saito A, Sankaran H, Goldfine I, Williams J . Cholecystokinin receptors in the brain: characterization and distribution. Science. 1980; 208(4448):1155-6. DOI: 10.1126/science.6246582. View

19.

Cohen S, Knight M, Tamminga C, Chase T . Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy. Eur J Pharmacol. 1982; 83(3-4):213-22. DOI: 10.1016/0014-2999(82)90254-0. View

20.

Hommer D, Pickar D, Roy A, Ninan P, Boronow J, Paul S . The effects of ceruletide in schizophrenia. Arch Gen Psychiatry. 1984; 41(6):617-9. DOI: 10.1001/archpsyc.1984.01790170091010. View